ClinicalTrials.Veeva

Menu

Association Between Plasma Melatonin and No-reflow

C

Chinese PLA General Hospital (301 Hospital)

Status

Completed

Conditions

ST-segment Elevation Myocardial Infarction

Study type

Observational

Funder types

Other

Identifiers

NCT03306303
MelandNR

Details and patient eligibility

About

ST-segment elevation myocardial infarction (STEMI) is an acute manifestation of coronary heart disease, remaining a frequent cause of death. A better understanding of risk factors and pathogenic mechanisms underlying STEMI may help improve the prognosis and life quality of these patients. Melatonin is the chief indoleamine produced by the pineal gland, and a well-known antioxidant and free radical scavenger. Basic studies have showed that melatonin is associated with myocardial infarction and heart failure. However, no study has evaluated whether melatonin is associated with adverse clinical outcomes in STEMI patients.

Enrollment

1,700 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

a diagnosis of STEMI and needed PCI

Exclusion criteria

patients with cancer patients who used melatonin

Trial design

1,700 participants in 4 patient groups

Quartile 1 of plasma melatonin
Description:
Quartile 1 of plasma melatonin
Quartile 2 of plasma melatonin
Description:
Quartile 2 of plasma melatonin
Quartile 3 of plasma melatonin
Description:
Quartile 3 of plasma melatonin
Quartile 4 of plasma melatonin
Description:
Quartile 4 of plasma melatonin

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems